| ■ 영문 제목 : Cell Dissociation Market Size, Share & Trends Analysis Report By Type (Cell Detachment, Tissue Dissociation), By Product (Enzymatic Dissociation), By End-user, By Region, And Segment Forecasts, 2023 - 2030
|
 | ■ 상품코드 : GRV23MR065
■ 조사/발행회사 : Grand View Research
■ 발행일 : 2023년 2월
■ 페이지수 : 150
■ 작성언어 : 영어
■ 보고서 형태 : PDF
■ 납품 방식 : E메일 (납기:3일)
■ 조사대상 지역 : 세계
■ 산업 분야 : 화학
|
■ 판매가격 / 옵션
(부가세 10% 별도)
| Single User (1인 열람용) | USD5,950 ⇒환산￦8,032,500 | 견적의뢰/주문/질문 |
| Multi User (5인 열람용) | USD6,950 ⇒환산￦9,382,500 | 견적의뢰/주문/질문 |
| Global/corporate License (기업 열람용) | USD8,950 ⇒환산￦12,082,500 | 견적의뢰/구입/질문 |
※가격옵션 설명
- 납기는 즉일~2일소요됩니다. 3일이상 소요되는 경우는 별도표기 또는 연락드립니다.
- 지불방법은 계좌이체/무통장입금 또는 카드결제입니다.
|
미국 Grand View Research (그랜드뷰리서치)의 본 조사 보고서는 세계의 세포 해리 시장 규모가 2023년부터 2030년 사이에 CAGR 13.55% 증가하여, 2030년에는 863.3백만 달러에 달할 것으로 전망하고 있습니다. 본 자료는 세계의 세포 해리 시장을 조사대상으로 하여, 조사 방법, 시장의 정의, 개요, 시장 변동/동향/범위, 제품별 (효소 해리, 비효소 해리, 기기 및 부속품) 분석, 종류별 (조직 해리, 세포 박리) 분석, 최종 용도별 (제약 및 바이오테크놀로지 기업, 연구 및 학술 기관) 분석, 지역별 (북미, 유럽, 아시아 태평양, 중남미, 중동 및 아프리카) 분석, 경쟁 현황 등의 내용을 게재하고 있습니다. 덧붙여 본 리포트는 Thermo Fisher Scientific Inc., Danaher Corporation, STEMCELL Technologies, Merck KGaA, BD, Sartorius AG, Miltenyi Biotec, PAN -Biotech, HiMedia Laboratories, F. Hoffmann -La Roche Ltd, S2 Genomics, Inc. 등의 기업 정보가 포함되어 있습니다.
・조사 방법
・시장 정의
・개요
・시장 변동/동향/범위
・세계의 세포 해리 시장 규모 : 제품별
- 효소 해리의 시장 규모
- 비효소 해리의 시장 규모
- 기기 및 부속품의 시장 규모
・세계의 세포 해리 시장 규모 : 종류별
- 조직 해리의 시장 규모
- 세포 박리의 시장 규모
・세계의 세포 해리 시장 규모 : 최종 용도별
- 제약 및 바이오테크놀로지 기업에서 사용되는 세포 해리의 시장 규모
- 연구 및 학술 기관에서 사용되는 세포 해리의 시장 규모
・세계의 세포 해리 시장 규모 : 지역별
- 북미의 세포 해리 시장 규모
- 유럽의 세포 해리 시장 규모
- 아시아 태평양의 세포 해리 시장 규모
- 중남미의 세포 해리 시장 규모
- 중동과 아프리카의 세포 해리 시장 규모
・경쟁 현황 |
■ 보고서 개요Cell Dissociation Market Growth & Trends
The global cell dissociation market size is expected to reach USD 863.3 million by 2030, registering a CAGR of 13.55% of the overall revenue, according to a new report by Grand View Research, Inc. The rising prevalence of chronic and infectious diseases, coupled with the increasing focus on cell-based therapeutics, is boosting market growth. In addition, growing funding for cell-based research and increasing use of automated instruments are the key factors driving the industry. With the growing applications of patient-derived cells as a model system for research, the necessity for high-quality cell material is constantly developing. The capability to extract individual cells from tissues is presently a bottleneck for cell-based diagnostic technologies and remains vital in the areas of tissue engineering, emerging diagnostic methods, cancer research, and personalized medicine approaches.
Key challenges comprise the quality and yield or the purity and integrity of cells as well as reproducibility and throughput. To overcome these limitations, researchers from Institut für Politikwissenschaft are developing a mechanical tissue dissociation system based on counter-rotating rows of grinding teeth integrated into a standard 50 ml centrifuge tube. The COVID-19 pandemic influenced market growth positively. Cell dissociation and tissue dissociation are used to aid cell-based therapies, primarily using Mesenchymal Stromal Cells (MSCs). As a result, the usage of these enzymes increased due to the COVID-19 pandemic, which augmented market growth. In current years, stem cell therapy has become an advanced and promising scientific research topic.
The development of treatment methods has induced great opportunities. Stem cells have considerable potential to become one of the most significant aspects of medicine. In addition to the fact that they play a huge role in developing restorative therapy, their study also divulges additional information about the complex events that happen during human development. Moreover, there is a growing interest in improving stem cell culture, not only because cell culture is extensively used in basic research for studying stem cell biology but also due to the potential therapeutic applications of cultured stem cells. Dissociation plays an important role in various research and therapeutic applications, including drug discovery, development, and cell therapy.
Furthermore, increasing clinical trials, FDA approvals, and strategic initiatives, such as collaborations by major players, are boosting industry growth. For instance, in October 2021, RHEACELL, a biopharmaceutical company headquartered in Germany, focused on the clinical development of innovative stem cell therapeutics, received national approval under the German Medicinal Products Act for its cell therapy product AMESANAR. In February 2023, IASO Biotherapeutics received Regenerative Medicine Advanced Therapy designation and Fast Track designation from USFDA for its IND BCMA CAR-T CT103A for relapsed/refractory multiple myeloma. Stringent regulations for raw materials and ethical issues concerning animal-derived products might hamper the industry’s growth to a certain extent.
The guidelines for the manufacturing of cell therapy products are still progressing. Still, the relevant reference is the USP 1046, which designates the significance of qualifying raw materials used in the manufacturing process. Thus, considering the concerns, such as raw material consistency, origin, risk of impurity, and whether the raw material was manufactured under the GMP guidelines, is significant for approval. However, there is a growing interest in Animal-origin free and GMP-grade enzymes, which will drive the industry growth during the forecast period. North America dominated the global industry in 2022 due to the high incidence of chronic diseases, the rise in investment funding by the government for cell therapy, and the presence of high-quality infrastructure for laboratory and clinical research.
Cell Dissociation Market Report Highlights
• The enzymatic dissociation product segment accounted for the highest share in 2022 due to increased requirements and the importance of enzymatic dissociation products for pharmaceutical & biotechnology companies, which, in turn, is likely to boost the adoption and anticipate the segment growth
• The tissue dissociation type segment held the largest revenue share in 2022 owing to the increased R&D activities and high prevalence of chronic disorders
• The biopharmaceutical & pharmaceutical companies end-user segment led the industry in 2022 owing to growth in clinical trials of cell-based therapeutics, FDA approvals, and research on cell & gene therapy
• The Asia Pacific region is expected to register the fastest growth rate during the forecast period
• This is owing to the rising demand for novel therapeutics and rapid infrastructural development
■ 보고서 목차Table of Contents
Chapter 1 Research Methodology
1.1 Market Segmentation & Scope
1.1.1 Estimates And Forecast Timeline
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased Database
1.3.2 GVR’s Internal Database
1.3.3 Secondary Sources
1.3.4 Primary Research
1.3.5 Details Of Primary Research
1.4 Information Or Data Analysis
1.4.1 Data Analysis Models
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Commodity Flow Analysis
1.6.1.1 Approach 1: Commodity flow approach
1.6.1.2 Approach 2: Country-wise market estimation using bottom-up approach
1.7 Global Market: CAGR Calculation
1.8 Research Assumptions
1.9 List of Secondary Sources
1.10 List of Primary Sources
1.11 Objectives
1.11.1 Objective 1:
1.11.2 Objective 2:
1.12 List of Abbreviations
Chapter 2 Market Definitions
Chapter 3 Executive Summary
3.1 Market Summary
Chapter 4 Global Cell Dissociation Market Variables, Trends, & Scope
4.1 Cell Dissociation Market Lineage Outlook
4.1.1 Parent Market Outlook
4.2 Penetration And Growth Prospect Mapping
4.3 Market Driver Analysis
4.3.1 Rising Focus On The Development Of Cell-Based Therapeutics
4.3.2 Growing Funding For Cell-Based Research
4.3.3 Technological Advancements In Cell Dissociations Instruments
4.4 Market Restraint Analysis
4.4.1 Stringent Regulations
4.5 Market Opportunity Analysis
4.5.1 Growing Emphasis On Stem Cell Research
4.6 Porter’s Five Forces Analysis
4.7 Cell Dissociation Market: COVID-19 Impact Analysis
Chapter 5 Cell Dissociation Market – Segment Analysis, by Product, 2018 – 2030 (USD Million)
5.1 Global Cell Dissociation Market: Product Movement Analysis
5.2 Enzymatic Dissociation
5.2.1 Enzymatic Dissociation market estimates and forecast, 2018-2030, USD million
5.2.2 Trypsin
5.2.2.1 Trypsin market estimates and forecast, 2018-2030, USD million
5.2.3 Collagenase
5.2.3.1 Collagenase market estimates and forecast, 2018-2030, USD million
5.2.4 Elastase
5.2.4.1 Elastase market estimates and forecast, 2018-2030, USD million
5.2.5 Papain
5.2.5.1 Papain market estimates and forecast, 2018-2030, USD million
5.2.6 Hyaluronidase
5.2.6.1 Hyaluronidase market estimates and forecast, 2018-2030, USD million
5.2.7 DNase
5.2.7.1 DNase market estimates and forecast, 2018-2030, USD million
5.2.8 Others
5.2.8.1 Others market estimates and forecast, 2018-2030, USD million
5.3 Non-Enzymatic Dissociation
5.3.1 Non-Enzymatic dissociation market estimates and forecast, 2018-2030, USD million
5.4 Instruments & Accessories
5.4.1 Instruments & accessories market estimates and forecast, 2018-2030, USD million
Chapter 6 Cell Dissociation Market – Segment Analysis, by Type, 2018 – 2030 (USD Million)
6.1 Global Cell Dissociation Market: Type Movement Analysis
6.2 Tissue Dissociation
6.2.1 Tissue dissociation market estimates and forecast, 2018-2030, USD million
6.3 Cell Detachment
6.3.1 Cell detachment market estimates and forecast, 2018-2030, USD million
Chapter 7 Cell Dissociation Market- Segment Analysis, by End-user, 2018 – 2030 (USD Million)
7.1 Cell Dissociation Market: End-user Movement Analysis
7.2 Pharmaceutical And Biotechnology Companies
7.2.1 Pharmaceutical And Biotechnology Companies market estimates and forecast, 2018-2030, USD million
7.3. Research & Academic Institutes
7.3.1 Research & academic institutes market estimates and forecast, 2018-2030, USD million
Chapter 8 Cell Dissociation Market: – Segment Analysis, by Region, 2018 – 2030 (USD Million)
8.1 Cell Dissociation Market: Regional Movement Analysis
8.2 North America
8.2.1 SWOT analysis
8.2.1.1 North America cell dissociation market, 2018 – 2030 (USD Million)
8.2.2 U.S.
8.2.2.1 Key country dynamics
8.2.2.2 Target disease prevalence
8.2.2.3 Competitive scenario
8.2.2.4 Regulatory framework
8.2.2.5 U.S. cell dissociation market, 2018 – 2030 (USD Million)
8.2.3 Canada
8.2.3.1 Key country dynamics
8.2.3.2 Target disease prevalence
8.2.3.3 Competitive scenario
8.2.3.4 Regulatory framework
8.2.3.5 Canada cell dissociation market, 2018 – 2030 (USD Million)
8.3 Europe
8.3.1 SWOT Analysis
8.3.1.1 Europe cell dissociation market, 2018 – 2030 (USD Million)
8.3.2 Germany
8.3.2.1 Key country dynamics
8.3.2.2 Target disease prevalence
8.3.2.3 Competitive scenario
8.3.2.4 Regulatory framework
8.3.2.5 Germany cell dissociation market, 2018 – 2030 (USD Million)
8.3.3 U.K.
8.3.3.1 Key country dynamics
8.3.3.2 Target disease prevalence
8.3.3.3 Competitive scenario
8.3.3.4 Regulatory framework
8.3.3.5 U.K. cell dissociation market, 2018 – 2030 (USD Million)
8.3.4 France
8.3.4.1 Key country dynamics
8.3.4.2 Target disease prevalence
8.3.4.3 Competitive scenario
8.3.4.4 Regulatory framework
8.3.4.5 France cell dissociation market, 2018 – 2030 (USD Million)
8.3.5 Italy
8.3.5.1 Key country dynamics
8.3.5.2 Target disease prevalence
8.3.5.3 Competitive scenario
8.3.5.4 Regulatory framework
8.3.5.5 Italy cell dissociation market, 2018 – 2030 (USD Million)
8.3.6 Spain
8.3.6.1 Key country dynamics
8.3.6.2 Target disease prevalence
8.3.6.3 Competitive scenario
8.3.6.4 Regulatory framework
8.3.6.5 Spain cell dissociation market, 2018 – 2030 (USD Million)
8.3.7 Denmark
8.3.7.1 Key country dynamics
8.3.7.2 Target disease prevalence
8.3.7.3 Competitive scenario
8.3.7.4 Regulatory framework
8.3.7.5 Denmark cell dissociation market, 2018 – 2030 (USD Million)
8.3.8 Sweden
8.3.8.1 Key country dynamics
8.3.8.2 Target disease prevalence
8.3.8.3 Competitive scenario
8.3.8.4 Regulatory framework
8.3.8.5 Sweden cell dissociation market, 2018 – 2030 (USD Million)
8.3.9 Norway
8.3.9.1 Key country dynamics
8.3.9.2 Target disease prevalence
8.3.9.3 Competitive scenario
8.3.9.4 Regulatory framework
8.3.9.5 Norway cell dissociation market, 2018 – 2030 (USD Million)
8.4 Asia Pacific
8.4.1 SWOT Analysis
8.4.1.1 Asia Pacific cell dissociation market, 2018 – 2030 (USD Million)
8.4.2 Japan
8.4.2.1 Key country dynamics
8.4.2.2 Target disease prevalence
8.4.2.3 Competitive scenario
8.4.2.4 Regulatory framework
8.4.2.5 Japan cell dissociation market, 2018 – 2030 (USD Million)
8.4.3 China
8.4.3.1 Key country dynamics
8.4.3.2 Target disease prevalence
8.4.3.3 Competitive scenario
8.4.3.4 Regulatory framework
8.4.3.5 China cell dissociation market, 2018 – 2030 (USD Million)
8.4.4 India
8.4.4.1 Key country dynamics
8.4.4.2 Target disease prevalence
8.4.4.3 Competitive scenario
8.4.4.4 Regulatory framework
8.4.4.5 India cell dissociation market, 2018 – 2030 (USD Million)
8.4.5 South Korea
8.4.5.1 Key country dynamics
8.4.5.2 Target disease prevalence
8.4.5.3 Competitive scenario
8.4.5.4 Regulatory framework
8.4.5.5 South Korea cell dissociation market, 2018 – 2030 (USD Million)
8.4.6 Australia
8.3.9.1 Key country dynamics
8.4.6.2 Target disease prevalence
8.4.6.3 Competitive scenario
8.4.6.4 Regulatory framework
8.4.6.5 Australia cell dissociation market, 2018 – 2030 (USD Million)
8.4.7 Thailand
8.4.7.1 Key country dynamics
8.4.7.2 Target disease prevalence
8.4.7.3 Competitive scenario
8.4.7.4 Regulatory framework
8.4.7.5 Thailand cell dissociation market, 2018 – 2030 (USD Million)
8.5 Latin America
8.5.1 SWOT Analysis
8.5.1.1 Latin America cell dissociation market, 2018 – 2030 (USD Million)
8.5.2 Brazil
8.5.2.1 Key country dynamics
8.5.2.2 Target disease prevalence
8.5.2.3 Competitive scenario
8.5.2.4 Regulatory framework
8.5.2.5 Brazil cell dissociation market, 2018 – 2030 (USD Million)
8.5.3 Mexico
8.5.3.1 Key country dynamics
8.5.3.2 Target disease prevalence
8.5.3.3 Competitive scenario
8.5.3.4 Regulatory framework
8.5.3.5 Mexico cell dissociation market, 2018 – 2030 (USD Million)
8.5.4 Argentina
8.5.4.1 Key country dynamics
8.5.4.2 Target disease prevalence
8.5.4.3 Competitive scenario
8.5.4.4 Regulatory framework
8.5.4.5 Argentina cell dissociation market, 2018 – 2030 (USD Million)
8.6 MEA
8.6.1 SWOT Analysis
8.6.1.1 MEA cell dissociation market, 2018 – 2030 (USD Million)
8.6.2 South Africa
8.6.4.1 Key country dynamics
8.6.2.2 Target disease prevalence
8.6.2.3 Competitive scenario
8.6.2.4 Regulatory framework
8.6.2.5 South Africa cell dissociation market, 2018 – 2030 (USD Million)
8.6.3 Saudi Arabia
8.6.3.1 Key country dynamics
8.6.3.2 Target disease prevalence
8.6.3.3 Competitive scenario
8.6.3.4 Regulatory framework
8.6.3.5 Saudi Arabia cell dissociation market, 2018 – 2030 (USD Million)
8.6.4 UAE
8.6.4.1 Key country dynamics
8.6.4.2 Target disease prevalence
8.6.4.3 Competitive scenario
8.6.4.4 Regulatory framework
8.6.4.5 UAE cell dissociation market, 2018 – 2030 (USD Million)
8.6.5 Kuwait
8.6.5.1 Key country dynamics
8.6.5.2 Target disease prevalence
8.6.5.3 Competitive scenario
8.6.5.4 Regulatory framework
8.6.5.5 Kuwait cell dissociation market, 2018 – 2030 (USD Million)
Chapter 9 Competitive Landscape
9.1 Company Categorization
9.2 Company Market Positioning
9.3 Company Market Share Analysis, 2022
9.4 Company Heat Map Analysis
9.5 Strategy Mapping
9.6 Company Profiles/Listing
9.6.1 Thermo Fisher Scientific Inc.
9.6.1.1. Overview
9.6.1.2. Financial performance (Net Revenue/Sales/EBITDA/Gross Profit)
9.6.1.3. Product benchmarking
9.6.1.4. Strategic initiatives
9.6.2 Danaher Corporation
9.6.2.1. Overview
9.6.2.2. Financial performance (Net Revenue/Sales/EBITDA/Gross Profit)
9.6.2.3. Product benchmarking
9.6.2.4. Strategic initiatives
9.6.3 STEMCELL Technologies
9.6.3.1. Overview
9.6.3.2. Financial performance (Net Revenue/Sales/EBITDA/Gross Profit)
9.6.3.3. Product benchmarking
9.6.3.4. Strategic initiatives
9.6.4 Merck KGaA
9.6.4.1. Overview
9.6.4.2. Financial performance (Net Revenue/Sales/EBITDA/Gross Profit)
9.6.4.3. Product benchmarking
9.6.4.4. Strategic initiatives
9.6.5 BD
9.6.5.1. Overview
9.6.5.2. Financial performance (Net Revenue/Sales/EBITDA/Gross Profit)
9.6.5.3. Product benchmarking
9.6.5.4. Strategic initiatives
9.6.6 Sartorius AG
9.6.6.1. Overview
9.6.6.2. Financial performance (Net Revenue/Sales/EBITDA/Gross Profit)
9.6.6.3. Product benchmarking
9.6.6.4. Strategic initiatives
9.6.7 Miltenyi Biotec
9.6.7.1. Overview
9.6.7.2. Financial performance (Net Revenue/Sales/EBITDA/Gross Profit)
9.6.7.3. Product benchmarking
9.6.7.4. Strategic initiatives
9.6.8 PAN-Biotech
9.6.8.1. Overview
9.6.8.2. Financial performance (Net Revenue/Sales/EBITDA/Gross Profit)
9.6.8.3. Product benchmarking
9.6.8.4. Strategic initiatives
9.6.9 HiMedia Laboratories
9.6.9.1. Overview
9.6.9.2. Financial performance (Net Revenue/Sales/EBITDA/Gross Profit)
9.6.9.3. Product benchmarking
9.6.9.4. Strategic initiatives
9.6.10 F. Hoffmann-La Roche Ltd
9.6.10.1. Overview
9.6.10.2. Financial performance (Net Revenue/Sales/EBITDA/Gross Profit)
9.6.10.3. Product benchmarking
9.6.10.4. Strategic initiatives
9.6.11 S2 Genomics, Inc.
9.6.11.1. Overview
9.6.11.2. Financial performance (Net Revenue/Sales/EBITDA/Gross Profit)
9.6.11.3. Product benchmarking
9.6.11.4. Strategic initiatives
|
| ※본 조사보고서 [세계의 세포 해리 시장 (2023~2030) : 세포 박리, 조직 해리] (코드 : GRV23MR065) 판매에 관한 면책사항을 반드시 확인하세요. |
| ※본 조사보고서 [세계의 세포 해리 시장 (2023~2030) : 세포 박리, 조직 해리] 에 대해서 E메일 문의는 여기를 클릭하세요. |
※당 사이트에 없는 보고서도 취급 가능한 경우가 많으니 문의 주세요!
